TUESDAY, June 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the Sonu Band, an artificial intelligence-enabled, wearable medical device for at-home treatment of ...

The Food and Drug Administration said approved UroGen Pharma’s (URGN) Zusduri for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The agency pointed ...

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting Provided by GlobeNewswire Jun 16, 2025, 5:00:00 AM ...

Yeztugo (lenacapavir) is now the first and only HIV prevention option approved by the U.S. FDA that offers protection for six months. Yeztugo received FDA approval under Priority Review.

BAYRY’s 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe.

That makes Yeztugo a valuable and far more convenient tool for addressing an epidemic that led to around 1.3 million new infections and contributed to the deaths of 630,000 people globally in 2023 ...

An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

PRINCETON, N.J.-- (BUSINESS WIRE)--Jun 12, 2025--U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate ...

By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 1:15 pm ...